Prevention strategy of cardiotoxicity in cancer chemotherapy

doi:10.19401/j.cnki.1007-3639.2018.01.011

China Oncology ›› 2018, Vol. 28 ›› Issue (1): 75-80.doi: 10.19401/j.cnki.1007-3639.2018.01.011

Prevention strategy of cardiotoxicity in cancer chemotherapy

HAN Jinbin¹, WU Ning², HUA Yongqiang³, ZHU Fu⁴

1. Department of Traditional Chinese Medicine, Shanghai Ninth people's Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200033, China; 2. Department of Oncology, Gongli Hospital of Shanghai Pudong New District, Shanghai 200135, China; 3. Department of Integrative Oncology, Fudan University Shanghai Cancer Center, Department of Oncology, Shanghai Medical College, Fudan University, Shanghai 200032, China; 4. Department of Cardiology, Central Hospital of Shanghai Xuhui District, Shanghai 200031, China

Online:2018-01-30 Published:2018-02-07
Contact: ZHU Fu E-mail: zhufu@xh.sh.cn

Abstract

Abstract: The cardiotoxicity of chemotherapeutic drugs is receiving more and more attention. The incidence and severity of cardiotoxicity can be reduced by methods such as reducing the dose of drugs, adjusting administration, and using low toxic drugs in clinical practice. Besides, appLncation of cardioprotective agents is very important and agents including cardiovascular ones, dexrazoxane as well as Chinese medicine preparations are commonly used currently. However, effects of these agents used for cardioprotection during chemotherapy are limited, and their safety needs further verification.

Key words: Cardio-oncology, Cardiotoxicity, Chemotherapy, Dexrazoxane

HAN Jinbin, WU Ning, HUA Yongqiang, et al. Prevention strategy of cardiotoxicity in cancer chemotherapy[J]. China Oncology, 2018, 28(1): 75-80.

[1]	ZHU Jun, WU Xiaohua. Leading research progress and prospect of gynecological oncology in 2020 [J]. China Oncology, 2021, 31(4): 250-256.
[2]	CAI Shumo, TANG Jie, HUANG Xiao, HUANG Xiaowei, LIU Suping, KE Guihao, ZHENG Zhong, CHENG Xi, TANG Meiqin. Three-step chemotherapy treatment for platinum-sensitive recurrent ovarian cancer: a review of 20 cases [J]. China Oncology, 2021, 31(4): 330-334.
[3]	HU Xi’e , YANG Zhenyu , XUE Jingyi , YANG Ping , PENG Shujia , YUAN Lijuan , BAO Guoqiang . Research progress of single-cell sequencing in neoadjuvant chemotherapy for triple-negative breast cancer [J]. China Oncology, 2021, 31(3): 221-226.
[4]	HE Hesheng , YANG Yuqiong , LIU Yinhua , JIN Xiaoke , XU Youhai , YAO Junping , LIU Shanhao , YAN Jiawei , HUANG Dongping . Characteristic analysis of peripheral T-cell lymphoma associated with autoimmune hemolytic anemia [J]. China Oncology, 2021, 31(2): 121-125.
[5]	LI Lei , WANG Zhi , YOU Chunyuan . The relapse of primary cardiac high-grade B-cell lymphoma after remission: a case report [J]. China Oncology, 2021, 31(2): 156-160.
[6]	LI Panpan, ZHANG Zhuo. Analysis of prognostic factors in 42 cases of primary central nervous system lymphoma [J]. China Oncology, 2021, 31(12): 1194-1201.
[7]	YU Yi, CONG Qing, XU Congjian, JIANG Wei. The effect of PAFR on cisplatin sensitivity in ovarian cancer cells and its mechanism [J]. China Oncology, 2021, 31(11): 1063-1071.
[8]	LIU Jiawei, LI Dan, ZHAI Qing. Risk factors analysis of liver injury induced by chemotherapy in patients with breast cancer [J]. China Oncology, 2021, 31(1): 52-62.
[9]	YAN Fang, YING Mingzhen, CHEN Longpei, FU Qiang. Clinical observation of albumin-bound paclitaxel plus nedaplatin as first-line treatment in advanced esophageal squamous cell carcinoma patients [J]. China Oncology, 2020, 30(8): 632-635.
[10]	ZHANG Xiaomeng , MA Ningyi , ZHU Hongcheng , AI Dashan , REN Zhigang . Efficacy and prognostic factors of adjuvant radiotherapy combined with chemotherapy in patients with pancreatic cancer [J]. China Oncology, 2020, 30(7): 519-524.
[11]	YANG Yiqi , WU Hao , YIN Yongmei . Current status and controversy of cardio-oncology in breast cancer [J]. China Oncology, 2020, 30(6): 475-480.
[12]	SHI Zhiqiang , QIU Pengfei , LIU Yanbing , ZHAO Tong , SUN Xiao , CHEN Peng , WANG Chunjian , ZHANG Zhaopeng , CONG Binbin , WANG Yongsheng . Selective elimination of axillary surgery staging after neoadjuvant chemotherapy for HER2 positive and triple-negative breast cancer [J]. China Oncology, 2020, 30(3): 186-191.
[13]	NING Zhouyu, HUA Yongqiang, XU Litao, ZHUANG Liping, FENG Lanyun, CHEN Hao, WANG Peng, SHEN Yehua, LIN Junhua, CHEN Zhen, MENG Zhiqiang. Efficacy and safety of nab-paclitaxel plus gemcitabine in the treatment of advanced pancreatic cancer by transcatheter arterial chemotherapy: a retrospective study [J]. China Oncology, 2020, 30(2): 128-134.
[14]	CHENG Qi, YI Xiaofang. Research progress on ferroptosis in drug resistance of tumor [J]. China Oncology, 2020, 30(2): 148-153.
[15]	ZHANG Longfu , YAO Jiamei , JIANG Dongxian , HOU Yingyong , ZHANG Xin . BIM combined with Scribble predicts treatment effect from chemotherapy in advanced non-small cell lung cancer [J]. China Oncology, 2020, 30(11): 865-871.

Prevention strategy of cardiotoxicity in cancer chemotherapy

PDF

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments